Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.

Descriptive subgroup analyses showed a trend towards higher rates of RBC-TI ≥ 1.5 years with luspatercept compared with epoetin alfa across prespecified patient subgroups (Fig. 2 ), including patients with baseline serum erythropoietin ≤ 200 U/L (35.9% vs. 15.3%, odds ratio [OR] 3.10, 95% CI 1.76–5.47), non-mutated SF3B1 (21.5% vs. 13.9%, OR 1.70, 95% CI 0.70–4.15), and RS− status [24.5% vs. 16.0%, OR 1.70, 95% CI 0.63–4.62].

also in 53,322 other papers